Back to top

Analyst Blog

UCB recently presented data from a study wherein patients suffering from Parkinson’s disease (PD) were transferred from an oral PD medication to Neupro.

The non-interventional, observational study conducted in Germany enrolled 76 patients. Results indicate that switching over from oral PD medications could lead to an improvement in pre-existing gastrointestinal (GI) symptoms.

Data from the study was presented at the annual meeting of the American Academy of Neurology’s (AAN).

In Jul 2012, UCB launched Neupro in the US to treat signs and symptoms of advanced stage idiopathic PD and moderate-to-severe primary restless legs syndrome (RLS). The drug was cleared by the US Food and Drug Administration in Apr 2012. Neupro is marketed in four and three different dosage strengths, respectively, for the signs and symptoms of PD and RLS.

In Aug 2012, Neupro was approved in the EU for early and advanced PD as well as RLS. In Japan, it received approval in Dec 2012 for similar indications.

In 2012, Neupro recorded sales of €133 million. Currently approved products for the treatment of PD and RLS include GlaxoSmithKline's Requip.

UCB carries a Zacks Rank #1 (Strong Buy). We expect Cimzia, Vimpat and Neupro to continue performing well in 2013. A few weeks back, Vimpat was approved in the European Union (EU) as a single loading dose option for treating patients suffering from partial onset seizures.

Additionally, UCB announced new regulatory filings with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for two additional indications for Cimzia.

Pharma stocks which currently look equally attractive are Lannett Company, Inc. and WuXi Pharma Tech (Cayman) Inc. , which carry a Zacks Rank #1.

Please login to Zacks.com or register to post a comment.